A Phase 3 Extension Study to Continue Pelabresib Treatment and Follow-up in Adults With Blood Cancers, Solid Tumors, or Advanced Malignancies

What this Trial Is About

Researchers are evaluating the long-term safety and clinical benefits of pelabresib in patients with blood cancers, solid tumors, or advanced malignancies. This Phase 3 study also includes participants who were previously enrolled in pelabresib studies, either continuing treatment or participating for survival follow-up to assess leukemia-free survival for blood cancer patients or overall survival for others. Participants eligible for continued pelabresib treatment will receive the drug at the same dose and schedule as in their previous study unless dose adjustments are needed due to side effects. Those who discontinued pelabresib or received placebo in prior studies may enroll for survival follow-up only. The study includes an eligibility check period of up to 28 days before treatment starts. During the study, participants will be monitored for side effects, disease status, and survival for up to five years. Safety follow-up visits occur about 30 days after the last pelabresib dose to assess any adverse events. Participants may be followed by telephone if they cannot return in person. The study will end when all parent studies close and participants complete safety follow-up or discontinue treatment permanently.

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib